« Back
Home /
Bleomycin (sulfate)

Bleomycin (sulfate)

Item no.	HY-17565-100mg
Manufacturer	MedChem Express
CASRN	9041-93-4
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Skin Cancer Colorectal Cancer
Type	Inhibitors
Specific against	other
Purity	99.62
Citations	[1]Hovhannisyan G, et al. Comparative analysis of individual chromosome involvement in micronuclei induced by bleomycin in human leukocytes. Mol Cytogenet. 2016 Jun 21;9:49.\|[2]Jaaskela-Saari HA, et al. Squamous cell cancer cell lines: sensitivity to bleomycin and suitability for animal xenograft studies. Acta Otolaryngol Suppl. 1997;529:241-4.\|[3]Corboz MR, et al. Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther. 2018 Apr;49:95-103.\|[4]Ling Peng, et al. Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial-mesenchymal transition and inflammation. Cell Death Dis. 2020 Nov 13;11(11):978.\|[5]Kang Miao, et al. Scutellarein inhibits BLM-mediated pulmonary fibrosis by affecting fibroblast differentiation, proliferation, and apoptosis. Ther Adv Chronic Dis. 2020 Jul 30;11:2040622320940185.\|[6]Brandt JP, et, al. Bleomycin. National Library of Medicine. August 28, 202\|[7]Gul A, et, al. Pulmonary fibrosis model of mice induced by different administration methods of bleomycin. BMC Pulm Med. 2023 Mar 21;23(1):91. ACS Appl Mater Interfaces. 2019 Jan 16;11(2):1942-1950. \|Am J Physiol Endocrinol Metab. 2024 Aug 28.\|Antioxidants (Basel). 2024 May 29;13(6):667.\|Biochem Biophys Res Commun. 2020 Jun 30;527(3):662-667.\|Biochem Cell Biol. 2025 Jan 1:103:1-7.\|Biochem Pharmacol. 2020 Apr;174:113846.\|Biochem Pharmacol. 2024 Aug 17:116496.\|Biochim Biophys Acta Mol Basis Dis. 2025 Mar 12;1871(5):167798.\|Biomed Pharmacother. September 2022, 113460.\|bioRxiv. 2024 July 27.\|bioRxiv. 2024 Nov 06.\|Cell Death Dis. 2020 Jun 15;11(6):464.\|Cell Death Dis. 2020 Nov 12;11(11):976.\|Cell Mol Biol Lett. 2024 Aug 30;29(1):115.\|Cell Mol Life Sci. 2024 Apr 18;81(1):187.\|Cell Rep. 2024 Sep 28;43(10):114794.\|Cell Rep. 2025 Mar 12;44(3):115399.\|Cells. 2021, 10(2), 202.\|Cells. 2022 Dec 29;12(1):145.\|Cells. 2023, 12(1), 145.\|Chinese Journal of Plastic and Reconstructive Surgery. 23 December 2021.\|Commun Biol. 2025 Jan 14;8(1):51.\|Eur J Pharmacol. 2024 Jul 26:176843.\|FEBS J. 2024 Aug 26.\|Front Pharmacol. 2022 May 20;13:911945.\|Fundam Res. 23 December 2021.\|Gene Rep. 2023 Jul 22, 101823.\|Genes Cells. 2025 Jan;30(1):e13192.\|Heliyon. 2024 June 23.\|Int Immunopharmacol. 2023 Jan 23;116:109723.\|Int Immunopharmacol. 2023 Sep 15;124(Pt A):110905.\|Int Immunopharmacol. 2024 Jul 6:138:112645.\|J Adv Res. 2024 Jun 19:S2090-1232(24)00254-6.\|J Ethnopharmacol. 2024 Apr 25:330:118226.\|Mech Ageing Dev. 2024 Jan 11:111902.\|Mutat Res Genet Toxicol Environ Mutagen. 2016 Sep 15;808:27-37. \|Naunyn Schmiedebergs Arch Pharmacol. 2024 Jun 14.\|Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov 16.\|OncoImmunology. 2020 Sep 22;9(1):1824631.\|Patent. US20190255042A1.\|Patent. US20190282565A1.\|Phytomedicine. 2023 Feb 11.\|Phytomedicine. 2024 Jun 3:131:155797.\|Research Square Preprint. 2023 Aug 30.\|Research Square Preprint. 2023 Nov 23.\|Research Square Print. November 28th, 2022.\|Respir Res. 2020 Nov 2;21(1):290.\|Respir Res. 2020 Feb 19;21(1):58. \|Stem Cell Res Ther. 2025 Jan 5;16(1):2.\|Toxicol Lett. 2022 Apr 23;363:45-54.\|Universidad de las Illes Balears. Facultad de Ciencias, 2022 Feb.\|Am J Respir Cell Mol Biol. 2021 Apr 16.\|Am J Respir Cell Mol Biol. 2021 Mar 24.\|Am J Respir Cell Mol Biol. 2021 Oct 28.\|Biochem Biophys Res Commun. 2024 Nov 4:739:150951.\|Biomed Pharmacother. 2021, 111500.\|Biomed Res Int. 2022 Feb 7;2022:8752325.\|Bioorg Med Chem. 2024 Sep 12.\|Cancer Lett. 2022 Feb 9;532:215588.\|Cancers (Basel). 2024 Aug 21;16(16):2902.\|Cell Death Dis. 2020 Nov 13;11(11):978.\|Cell Signal. 2021 Aug 4;110106.\|Chin Med. 2023 May 24;18(1):60.\|Clin Epigenetics. 2023 Nov 11;15(1):182.\|Exp Mol Med. 2024 Dec 6.\|Heliyon. 2023 Nov 13.\|Heliyon. 2024 Sep 20;10(19):e38122.\|Immunopharmacol Immunotoxicol. 2020 Oct;42(5):436-444.\|Int Immunopharmacol. 2025 Mar 7:152:114392.\|J Cell Biol. 2021 Feb 1;220(2):e201911025.\|J Control Release. 2023 Aug;360:365-375.\|J Inflamm Res. 2024 Jun 19:17:3983-3999.\|J Transl Med. 2024 Apr 1;22(1):323.\|J Transl Med. 2024 Nov 21;22(1):1051.\|J Transl Med. 2025 Jan 2;23(1):3.\|Life Sci. 2021 Jan 1;264:118664.\|MedComm Futur Med. 2024 Jul 19.\|Mediat Inflamm. 03 Mar 2022.\|Mol Metab. 2022 Jun 2;101524.\|Nat Cell Biol. 2024 Jul 12.\|Nat Metab. 2021 Dec 6.\|Nat Prod Commun. 2024 Mar 29.\|Oxid Med Cell Longev. 01 Nov 2021.\|Oxid Med Cell Longev. 30 Jun 2021.\|Pharmaceuticals (Basel). 2024 Oct 11;17(10):1360.\|Phytomedicine. 2024 Jul 27:133:155882.\|Phytother Res. 2022 Jul 6.\|Redox Biol. 2021 Jul 26;46:102082.\|Res Sq. 2024 Oct 31.\|Research Square Preprint. 2023 Aug 4.\|Respir Res. 2024 Oct 19;25(1):382.\|Rheumatol Autoimmun. 2024 Jun 28.\|Sci China Life Sci. 2023 Jun 16.\|Sci Rep. 2023 Jun 28;13(1):10485.\|Small. 2021 Oct 8;e2103919.\|Ther Adv Chronic Dis. 2020 Jul 30;11:2040622320940185.\|Biomed Pharmacother. 2024 Jan 15:171:116101.\|Biomedicines. 2023, 11(2), 463.\|BMC Pharmacol Toxicol. 2024 Feb 14;25(1):18.\|BMC Pulm Med. 2023 Nov 13;23(1):440.\|Cancer Lett. 2023 Feb 15;558:216092.\|Exp Ther Med. 2024 Jan 4.\|Front Biosci (Landmark Ed). 2023 Sep 22, 28(9), 209.\|Inflammation. 2023 May 9.\|Inflammation. 2024 Mar 18.\|Int Immunopharmacol. 2022, 113: 109409.\|Int Immunopharmacol. 2023 May 22;120:110369.\|Int J Biol Macromol. 2023 Apr 17;124476.\|J Gene Med. 2022 Sep 30;e3451.\|MedComm. 2023 Jul 12;4(4):e319.\|Mol Med. 2023 Mar 14;29(1):32.\|Molecules. 2023, 28(2), 753.\|Nat Commun. 2022 Nov 17;13(1):7028.\|Phytomedicine. 2023 Jun 17, 154919.\|Research Square Preprint. 2023 Aug 3.\|Transl Res. 2023 Feb 6;S1931-5244(23)00018-X.
Smiles	O=C(C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C)N[C@H](C(N[C@H](C)[C@@H](O)[C@H](C)C(N[C@]([C@H](O)C)([H])C(NCCC2=NC(C3=NC(C(N[R])=O)=CS3)=CS2)=O)=O)=O)[C@H](C4=CN=CN4)O[C@H]5[C@H]([C@H]([C@@H]([C@@H](O5)CO)O)O)O[C@]6([H])[C@H]([C@H]([C@@H]([C@H](O6)CO)O)OC(N)=O)O.NC(NCCCC[R])=N.[R]CCC[S+](C)C.O=S(O)(O)=O.[R=].[Bleomycin A2].[R=].[Bleomycin B2]
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Bleomycin sulfate
Shipping Condition	Room temperature
Available
Manufacturer - Type	Natural Products
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Antibiotic; DNA/RNA Synthesis
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	1523 (average)
Product Description	Bleomycin sulfate is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin sulfate is an antitumor antibiotic[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 41.67 mg/mL (ultrasonic)\|H2O: 255 mg/mL (ultrasonic; warming)
Manufacturer - Pathway	Anti-infection; Cell Cycle/DNA Damage
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-17565-100mg-safety-datasheet.pdf